Research - Westmount, Quebec, Canada
Mperia Therapeutics is the CD36 Therapeutics Development Company. Lead candidates applied to macrophage-driven inflammation via CD36 receptor immuno-metabolism mediation. Showing clear efficacy in pre-clinical models for dry age-related macular degeneration (dry AMD), atherosclerosis and NASH.
Outlook